Lag-3 and Gemcitabine for Treatment of Advanced Pancreas Cancer
Status:
Terminated
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The overall purpose of this research is to evaluate the safety and toxicity of an
investigational medication, IMP321, in patients being treated with gemcitabine. IMP321 is a
synthetic protein (made in the laboratory to simulate a protein that your body makes on its
own) and was designed to stimulate the immune system with the overall objective of improving
the body's capacity to react to your pancreas cancer.